

[241] MONITORING CHRONIC INFLAMMATION - PROACTIVE DIAGNOSTICS

Reuven Duer¹, ¹ Proactive Diagnostics

Monitoring Chronic Inflammation - Proactive Diagnostics

- **Investment Rational**

Chronic inflammation (CI) is the result as well as the root-cause of most illnesses in the developed world. These illnesses include cancer, cardiovascular diseases and neuro-degenerative diseases such as Alzheimer disease. Therefore, routine monitoring chronic inflammation can make a huge difference in terms of early detection, guiding therapeutics and disease management. While millions of people are hurting there is currently no monitoring solutions out there.
- **Business Strategy**

To address the above needs, Proactive Diagnostics is developing a Direct to Consumer (DTC) diagnostic product to quantify known acute and chronic inflammation biomarkers using sub-10 μ L finger-prick blood. For an affordable price of \$5/test and results available in 5-minutes, people will receive an accurate snap-shots of their current state of inflammation on an 'as-needed' basis, at the comfort of their own home. The results will be presented on their mobile device and can be shared with the primary physician. Combined with other personal information (e.g. food consumed, stress level workout, and sleeping hours) as well as local environmental information (e.g. allergen counts and air-pollution) it will help identify the personal inflammation triggers and empower individuals to be in charge of their health.
- **Core Technology**

Proactive Diagnostics has developed an enabling detection technology utilizing silicon-based waveguide chips which enables moving diagnostics to the point of care and to the home. This disrupting technology enables the quantification of multiple (32) biomarkers from a single drop of blood (<10ul) in five minutes and performance comparable or better than a central lab.
- **Company Profile**

Technology development complete
Fully function prototype with quality feasibility data
12 granted patents
Small but experience team
Collaboration with a top assay development company having a 13-plex inflammation panel
- **What's Next?**

12 months to complete product development
18-24 months for product validation and verification and regulatory submission
Launch online social-media campaign for engaging a community of future users
Total funding required \$30M in three rounds